Six months ago, I bought shares of Nuvectra Corporation (NASDAQ:NVTR), a small US medical device company which has developed a platform for the treatment of neurological disorders, which was separated via spin-off from Greatbatch. A month after buying it, it increased by over 100% and was sold out of the portfolio. I bought the stock not because I’m an expert in the field, but because of the great pricing distortion in which the stock traded - it was traded at a market value of $48 million while it had $75 million of cash on hand and zero debt. The story of Aptevo Therapeutics (NASDAQ:APVO) seems to be very similar to that of NVTR.
